title: Arabinoxylan fibre consumption improved glucose metabolism, but did not affect serum adipokines in subjects with impaired glucose tolerance.
abstract: The consumption of arabinoxylan, a soluble fibre fraction, has been shown to improve glycemic control in type 2 diabetic subjects. Soluble dietary fibre may modulate gastrointestinal or adipose tissue hormones regulating food intake. The present study investigated the effects of arabinoxylan consumption on serum glucose, insulin, lipids, leptin, adiponectin and resistin in subjects with impaired glucose tolerance. In a randomized, single-blind, controlled, crossover intervention trial, 11 adults consumed white bread rolls as either placebo or supplemented with 15 g arabinoxylan for 6 weeks with a 6-week washout period. Fasting serum glucose, insulin, triglycerides, unesterified fatty acids, apolipoprotein A1 and B, adiponectin, resistin and leptin were assessed before and after intervention. Fasting serum glucose, serum triglycerides and apolipoprotein A-1 were significantly lower during arabinoxylan consumption compared to placebo (p=0.029, p=0.047; p=0.029, respectively). No effects of arabinoxylan were observed for insulin, adiponectin, leptin and resistin as well as for apolipoprotein B, and unesterified fatty acids. In conclusion, the consumption of AX in subjects with impaired glucose tolerance improved fasting serum glucose, and triglycerides. However, this beneficial effect was not accompanied by changes in fasting adipokine concentrations.
authors.affiliation: Dietary Fibre and the Metabolic Syndrome Group, German Institute of Human Nutrition, Potsdam-Rehbruecke, Nuthetal, Germany.
authors.forename: A L
authors.initials: AL
authors.lastname: Garcia
authors.forename: J
authors.initials: J
authors.lastname: Steiniger
authors.forename: S C
authors.initials: SC
authors.lastname: Reich
authors.forename: M O
authors.initials: MO
authors.lastname: Weickert
authors.forename: I
authors.initials: I
authors.lastname: Harsch
authors.forename: A
authors.initials: A
authors.lastname: Machowetz
authors.forename: M
authors.initials: M
authors.lastname: Mohlig
authors.forename: J
authors.initials: J
authors.lastname: Spranger
authors.forename: N N
authors.initials: NN
authors.lastname: Rudovich
authors.forename: F
authors.initials: F
authors.lastname: Meuser
authors.forename: J
authors.initials: J
authors.lastname: Doerfer
authors.forename: N
authors.initials: N
authors.lastname: Katz
authors.forename: M
authors.initials: M
authors.lastname: Speth
authors.forename: H J F
authors.initials: HJ
authors.lastname: Zunft
authors.forename: A H F
authors.initials: AH
authors.lastname: Pfeiffer
authors.forename: C
authors.initials: C
authors.lastname: Koebnick
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D001823:Body Composition / Q000502:physiology; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D004043:Dietary Fiber / Q000627:therapeutic use*; D005260:Female; D005947:Glucose / Q000378:metabolism*; D018149:Glucose Intolerance / Q000188:drug therapy* / Q000378:metabolism*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D052243:Resistin / Q000097:blood; D016037:Single-Blind Method; D014280:Triglycerides / Q000097:blood; D014990:Xylans / Q000627:therapeutic use*
chemical_list: D052242:Adiponectin; D001786:Blood Glucose; D002784:Cholesterol; D004043:Dietary Fiber; D005947:Glucose; D006442:Glycated Hemoglobin; D007328:Insulin; D020738:Leptin; D008055:Lipids; D052243:Resistin; D014280:Triglycerides; D014990:Xylans; C085118:arabinoxylan